**DISCOVERY**

Discovery is a three-stage process consisting of compound screening, lead selection, and lead optimization. The objective is to identify drug candidates that meet a predetermined set of criteria to enter the clinical development process. DNDi has entered into a number of partnerships aimed at ensuring that a robust portfolio is built by 2018.

**Pre-clinical Development**

- **Phase I**
  - Fexinidazole (HAT)
    - Objective: To undertake the clinical development of fexinidazole, the first orally administered drug candidate in clinical phase for sleeping sickness. Fexinidazole entered into Phase I first-in-human clinical studies in September 2009. Phase II clinical studies will start in early 2012. DNDi and Sanoﬁ have signed an agreement for the development, manufacturing, and distribution of fexinidazole.
    - Major Partners:
      - Sanoﬁ, France; Swiss TPH, Switzerland; HAT Platform partners.

**Clinical Development**

- **HAT Consortium**
  - Objective: To obtain optimized leads by progressing 'hits' with a good safety profile and activity against Trypanosoma brucei parasites.
  - Partners:
    - Anacor, USA; SCYNEXIS, USA; Pace University, USA; with the support of Swiss TPH, Switzerland.

**Implementation**

- **NECT-Field – Nifurtimox-Emilior Co-administration Therapy (HAT)**
  - Objective: The Phase IIIb NECT-Field study in DRC will further document the safety and ease of use of the combination in real-life field conditions and in new populations, such as pregnant and breastfeeding women, and children.

- **Nitroimidazole Back-up (HAT)**
  - Objective: In case the clinical development of a potential drug in development for HAT fails to meet the expected profiles, DNDi is undertaking the pre-clinical development of a back-up drug candidate from the nitroimidazoles proactive screening project.
  - Partners:
    - TB Alliance, USA; Swiss TPH, Switzerland; Suwinski, Poland.

- **Oxaborole SCYX-7158 (HAT)**
  - Objective: To undertake the pre-clinical development of oxaboroles – a boron-based compound series originated by Anacor. During the course of the collaboration, chemists at ... SCYX-7158, a promising new drug candidate for HAT, will be advanced into Phase I first-in-human clinical studies in 2011.
  - Partners:
    - Anacor, USA; SCYNEXIS, USA; Pace University, USA; Advinus Therapeutics, India.